Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0DLHUL |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | huASCT2 17c10 mAb |
|||||
| Synonyms |
huASCT2 17c10 mAb
Click to Show/Hide
|
|||||
| Antigen Name | Amino acid transporter (ASCT2) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
EP4471061A1 17c10_MC-Dxd [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
5- 2 × 10 -5 ug/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
135- 6.9 × 10 -3 g/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | WiDr cells | CVCL_2760 | ||
ICT_MC-Dxd (Isotype control) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
5- 2 × 10 -5 ug/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
135- 6.9 × 10 -3 g/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | WiDr cells | CVCL_2760 | ||
EP4471061A1 MC_Dxd [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9- 4.6 × 10 -4 ug/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9- 4.6 × 10 -4 ug/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | WiDr cells | CVCL_2760 | ||
EP4471061A1 17c10_betaGlu-EXA-2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
40- 1.53 × 10 -4 ug/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | WiDr cells | CVCL_2760 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
80- 3.05 × 10 -4 ug/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
ICT_betaGlu-EXA-2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
40- 1.53 × 10 -4 ug/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | WiDr cells | CVCL_2760 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
80- 3.05 × 10 -4 ug/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
betaGlu-EXA-2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2- 7.62 × 10 -4 g/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
30- 1.14 × 10 -4 g/mL
|
Positive ASCT2 expression (ASCT2+++/++) | ||
| Method Description |
Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | WiDr cells | CVCL_2760 | ||